Strategic Diversification Gubra operates across three synergistic units (Biotech, CRO Services, Ventures) with a strong emphasis on translational science and rapid program progression, presenting multiple entry points for collaboration, licensing, and co-development deals in therapeutic peptides and metabolic diseases.

Sustainability Advantage Gubra Green dedicates 10% of pre-tax profits to net-zero and nature-positive initiatives, signaling potential for sustainability-focused partnerships, ESG-aligned funding opportunities, and procurement preferences with like-minded biotechs and contract partners.

Clinical and Preclinical Expertise With in-house capabilities spanning in vivo pharmacology, ex vivo assays, peptide chemistry, AI-enhanced imaging, and bioinformatics, Gubra offers end-to-end preclinical services and next-generation peptide programs ripe for partnering or outsourcing.

Financial Footing Annual revenue in the 10–25 million USD range and a mid-sized employee base indicate a scalable partner for selective co-development, milestone-driven collaborations, and early-access licensing opportunities targeting metabolic disease programs.

Strategic Assets Lead obesity programs including ABBV-295 and BI 3034701, plus internal GUB-UCN2, provide concrete assets and clinical-stage potential for out-licensing, collaboration on Novo-type ventures, or accelerated programs through ventures and partnerships.